Faculty of Epidemiology & Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
PLoS One. 2022 Jun 6;17(6):e0269064. doi: 10.1371/journal.pone.0269064. eCollection 2022.
Recent studies indicate that vitamin D supplementation may decrease respiratory tract infections, but the association between vitamin D and COVID-19 is still unclear.
To explore the association between vitamin D status and infections, hospitalisation, and mortality due to COVID-19.
We used UK Biobank, a nationwide cohort of 500,000 individuals aged between 40 and 69 years at recruitment between 2006 and 2010. We included people with at least one serum vitamin D test, living in England with linked primary care and inpatient records. The primary exposure was serum vitamin D status measured at recruitment, defined as deficiency at <25 nmol/L, insufficiency at 25-49 nmol/L and sufficiency at ≥ 50 nmol/L. Secondary exposures were self-reported or prescribed vitamin D supplements. The primary outcome was laboratory-confirmed or clinically diagnosed SARS-CoV-2 infections. The secondary outcomes included hospitalisation and mortality due to COVID-19. We used multivariable Cox regression models stratified by summertime months and non-summertime months, adjusting for demographic factors and underlying comorbidities.
We included 307,512 participants (54.9% female, 55.9% over 70 years old) in our analysis. During summertime months, weak evidence existed that the vitamin D deficiency group had a lower hazard of being diagnosed with COVID-19 (hazard ratio [HR] = 0.86, 95% confidence interval [CI] = 0.77-0.95). During non-summertime, the vitamin D deficiency group had a higher hazard of COVID-19 compared with the vitamin D sufficient group (HR = 1.14, 95% CI = 1.01-1.30). No evidence was found that vitamin D deficiency or insufficiency was associated with either hospitalisation or mortality due to COVID-19 in any time strata.
We found no evidence of an association between historical vitamin D status and hospitalisation or mortality due to COVID-19, along with inconsistent results for any association between vitamin D and diagnosis of COVID-19. However, studies using more recent vitamin D measurements and systematic COVID-19 testing are needed.
最近的研究表明,维生素 D 补充剂可能会减少呼吸道感染,但维生素 D 与 COVID-19 之间的关联仍不清楚。
探讨维生素 D 状态与 COVID-19 感染、住院和死亡的关系。
我们使用了英国生物银行(UK Biobank),这是一个由 50 万人组成的全国性队列,他们在 2006 年至 2010 年间招募时年龄在 40 至 69 岁之间。我们纳入了至少进行过一次血清维生素 D 检测、居住在英格兰且有初级保健和住院记录的人群。主要暴露因素是招募时测量的血清维生素 D 状态,定义为<25 nmol/L 为缺乏,25-49 nmol/L 为不足,≥50 nmol/L 为充足。次要暴露因素为自我报告或处方的维生素 D 补充剂。主要结局是实验室确诊或临床诊断的 SARS-CoV-2 感染。次要结局包括 COVID-19 住院和死亡。我们使用多变量 Cox 回归模型,按夏季和非夏季月份进行分层,调整人口统计学因素和潜在合并症。
我们在分析中纳入了 307512 名参与者(54.9%为女性,55.9%年龄超过 70 岁)。在夏季月份,有微弱的证据表明维生素 D 缺乏组 COVID-19 的诊断风险较低(危险比 [HR] = 0.86,95%置信区间 [CI] = 0.77-0.95)。在非夏季月份,维生素 D 缺乏组 COVID-19 的风险高于维生素 D 充足组(HR = 1.14,95% CI = 1.01-1.30)。在任何时间分层,都没有证据表明维生素 D 缺乏或不足与 COVID-19 住院或死亡有关。
我们没有发现历史维生素 D 状态与 COVID-19 住院或死亡之间存在关联的证据,也没有发现维生素 D 与 COVID-19 诊断之间存在任何关联的一致性结果。然而,需要使用最近的维生素 D 测量值和系统的 COVID-19 检测进行研究。